Synergistic effects of luspatercept and cyclosporine A in lower-risk myelodysplastic syndrome with red cell aplasia: Two case insights
{{output}}
Luspatercept, an erythroid maturation agent, treats anemia in lower-risk myelodysplastic syndromes (MDS) by inhibiting SMAD2/3 signaling. However, its efficacy may be limited in immune-mediated erythroid suppression. We present two lower-risk MDS cases (per th... ...
